Novel Approaches to Diagnosing and Treating Generalized Pustular Psoriasis - Episode 10

Utilizing Intravenous and Subcutaneous Formulations of Spesolimab

Published on: March 29, 2025

Aaron Farberg, MD, FAAD , Harrison Nguyen, MD, MBA, MPH, FAAD , Boni Elewski, MD, FAAD , Johann Gudjonsson, MD, PhD, FAAD

Panelists compare the results of the EFFISAYIL-1 and -2 trials with real-world use of spesolimab; discuss treatment expectations with patients; and explore the similarities, differences, and management roles of intravenous (IV) and subcutaneous (SQ) formulations, with strategies for timely IV therapy initiation during flares.

Video content above is prompted by the following:

EP. 1: Clinical Presentation and Burden of Disease of Generalized Pustular Psoriasis

EP. 2: Impact of GPP Triggers and Flares on a Patient’s Physical and Mental Health

EP. 3: Approaches to Diagnosing GPP and Distinguishing It From Other Psoriatic Conditions

EP. 4: Challenges for Making a Timely GPP Diagnosis

EP. 5: GPP Pathogenesis and Treatment Goals

EP. 6: Older Treatment Approaches to GPP Management

EP. 7: Addressing the Psychosocial Aspects of GPP Management and the Role of Multidisciplinary Care

EP. 8: Role of IL-36 in GPP Pathogenesis and Treatment

EP. 9: Overview of Spesolimab for Management of GPP

Now Viewing

EP. 10: Utilizing Intravenous and Subcutaneous Formulations of Spesolimab

EP. 11: Future Directions for GPP Management and Key Takeaways

How do the results of EFFISAYIL-1 and -2 compare with the results you have seen with spesolimab in clinical practice?
a. How do you discuss treatment expectations for spesolimab with your patients?
Discuss the utility of both an IV and SQ formulation of spesolimab. How are they similar and different, and how are both formulations used in the management of GPP?
a. PK modeling (Hawkes, 2024)
b. How do you ensure timely initiation of IV therapy and continuity of care when a patient is experiencing a flare?